Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity Study of Tularemia Vaccine in Adults at Risk of Exposure
NCT03867162Phase 2Withdrawn
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NDBR 101 in tularemia, sponsored by U.S. Army Medical Research and Development Command. Planned start Jun 2021; status: withdrawn.
02
Drugs
NDBR 101
03
Conditions
tularemia
Beyond the preview
Go deeper on NCT03867162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867162.